Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Common Equity (2019 - 2026)

Enliven Therapeutics has reported Common Equity over the past 8 years, most recently at $453.4 million for Q1 2026.

  • Quarterly results put Common Equity at $453.4 million for Q1 2026, up 57.26% from a year ago — trailing twelve months through Mar 2026 was $453.4 million (up 57.26% YoY), and the annual figure for FY2025 was $459.6 million, up 48.33%.
  • Common Equity reached $453.4 million in Q1 2026 per ELVN's latest filing, down from $459.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $488.5 million in Q2 2025 and bottomed at -$76.8 million in Q4 2022.
  • Median Common Equity over the past 5 years was $288.4 million (2024), compared with a mean of $247.7 million.
  • The largest annual shift saw Common Equity crashed 190.37% in 2022 before it soared 675.81% in 2023.
  • Over 5 years, Common Equity stood at -$76.8 million in 2022, then soared by 420.09% to $245.9 million in 2023, then increased by 26.0% to $309.8 million in 2024, then skyrocketed by 48.33% to $459.6 million in 2025, then decreased by 1.36% to $453.4 million in 2026.
  • Business Quant data shows Common Equity for ELVN at $453.4 million in Q1 2026, $459.6 million in Q4 2025, and $476.1 million in Q3 2025.